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No Evidence in a Large UK Collection for
Celiac Disease Risk Variants Reported
by a Spanish Study
Dear Sir:
In their recent article, Castellanos-Rubio et al1 use
genome-wide expression profiling combined with pub-
lished data on genomic regions showing modest linkage
to celiac disease as a strategy to identify inherited genetic
variants predisposing to disease. They investigated 361
identified variants in a small case-control collection (262
cases, 214 controls) of Spanish origin. After quality con-
trol procedures 330 single nucleotide polymorphisms
(SNPs) were available for association testing: 10 SNPs
from 6 different genes/regions were stated to show evi-
dence of association with celiac disease (uncorrected P 
.005), with 4 SNPs remaining significant after statistics
were corrected for multiple testing. They suggested these
preliminary findings should be validated and tested in
different populations.1
We recently carried out a genome-wide association
study of 310,605 SNPs in 778 celiac cases and 1422
population controls from the British population.2 Such
studies have recently been shown to be highly effective to
identify risk variants for common disease.3 We previously
directly genotyped rs365836 in our UK celiac/control
genome-wide study,2 and have now imputed data for the
other 9 SNP markers analyzed by Castellanos-Rubio et
al1 using algorithms implemented in PLINK v1.0.0.4 We
found no evidence (Table 1, uncorrected P.05) in the
UK collection for 9 of the 10 associations reported in the
Spanish collection. Although rs6747096 was borderline
significant (uncorrected P  .016) in the UK collection,
the effect is in the opposite direction (rs6747096 G allele
is more frequent in UK cases versus controls, yet less
frequent in Spanish cases versus controls).1
There are a number of possible reasons for these
apparent discrepancies. First, the results of the study
by Castellanos-Rubio et al1 could be due to type 1
statistical error arising through the multiple hypothe-
sis testing of the 330 SNPs investigated. The authors
did correctly apply a Bonferroni correction. Second,
UK data may represent a type 2 error. However, the UK
collection is of much larger sample size, and power
calculations suggest adequate power (80% at P  .05
for all markers, using a multiplicative model and as-
suming celiac disease population prevalence of 1%) to
detect effects of the allele frequencies (as observed in
UK controls) and odds ratios as reported by Castella-
nos-Rubio et al.1 A third possible explanation is the
presence of genetic heterogeneity between the British
and Spanish populations. However, in our genetic in-
vestigations of celiac disease to date across Irish, Brit-
ish, and Dutch populations (8000 samples geno-
typed for 1000 SNPs) we have not yet observed any
evidence for heterogeneity at 8 non-HLA celiac disease
associated regions.5 Broadly similar disease prevalence
and clinical features are seen across European popula-
tions suggesting (with the possible exception of HLA-
DQ) that genetic heterogeneity is at most a minor
issue.
Multiple risk variants for common human diseases
have recently been identified by genome-wide association
studies.6 Most of these findings do not map to regions
previously identified by genetic linkage studies. In celiac
Table 1. Analysis of 10 Celiac Disease-Associated SNPs Reported Castellanos-Rubio et al1 in a UK Collection
SNP
Spanish (Castellanos-Rubio et al1) UK genome wide association study
Allele
1/2
MAF
cases
MAF
controls P value Method
Allele
minor/major
MAF
cases
MAF
controls P value
rs12619019 G/C 0.18 0.11 .0015 Imputation INFO  0.90 G/C 0.173 0.162 .33
rs6747096 G/A 0.16 0.29 2.38 105 Imputation INFO  0.97 G/A 0.211 0.182 .016
rs11954744 A/T 0.13 0.21 .0016 Imputation INFO  0.93 A/T 0.179 0.164 .19
rs6887645 A/G 0.13 0.21 .0022 Imputation INFO  0.93 A/G 0.180 0.164 .17
rs365836 G/A 0.24 0.33 .0016 Illumina Hap300 G/A 0.256 0.267 .40
rs1048251 T/G 0.53 0.40 3.02 104 Imputation INFO  1.03 T/G 0.464 0.444 .21
rs7019234 G/A 0.53 0.40 3.08 104 Imputation INFO  1.03 G/A 0.464 0.444 .21
rs459311 T/G 0.52 0.39 1.38 104 Imputation INFO  0.99 T/G 0.434 0.434 .21
rs458046 T/A 0.52 0.39 1.35 104 Imputation INFO  0.99 T/A 0.435 0.435 .21
rs7040561 T/A 0.15 0.06 6.55 105 Imputation INFO  0.77 T/A 0.157 0.141 .12
MAF, minor allele frequency.
SNP imputation was performed using celiac UKGWAS data2 merged with 2,244,775 high-quality SNPs from 60 CEU founders from the HapMap
project (http://pngu.mgh.harvard.edu/purcell/plink/pimputation.shtml). Quality (INFO, information) scores for all 9 imputed markers were
high.
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disease, consistent findings from linkage studies have not
been obtained. We feel the strategy pursued by Castella-
nos-Rubio et al1 (prioritizing linkage regions for associ-
ation studies) is suboptimal.
As Castellanos-Rubio et al discuss,1 there are often
discrepancies between the findings of candidate gene
association studies. We highlight the importance of
carrying out large, well-designed, genome-wide studies
with findings replicated in at least 1 other population.
(Table 1)
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Reply. In a letter regarding our recent association study
in celiac disease (CD) performed after combining mi-
croarray expression profiling of intestinal biopsies with
previously identified linkage regions as a candidate gene
selection strategy,1 Hunt et al claim to have failed to
replicate any of our results in their UK case/control
sample from a recent genome-wide association study
(GWAS).2 With the exception of rs365836 (weakly asso-
ciated in our study, uncorrected P  .0016) association
analyses were performed on imputed single nucleotide
polymorphism (SNP) data, obtained using a procedure
available in PLINK v.1.0 to simulate genotypes for un-
typed SNPs.3 There are several possible explanations for
these apparent discrepancies, some of which have already
been addressed by Hunt et al in their letter. Herein, we
would like to draw attention to other possible contrib-
uting factors.
First, we believe that one must be cautious when
using a single SNP imputation algorithm as the only
tool to detect (or discard) disease association. In the
particular case of the imputation option available in
PLINK, the author advises on the exploratory and beta
nature of the procedures and interpretation of the
results (http://pngu.mgh.harvard.edu/purcell/plink/
pimputation.shtml). SNP imputation methods that
can recover information from unavailable genotypes
can certainly increase the power to detect genotype–
phenotype associations; correcting for genotyping er-
rors at certain SNPs, as well as fine-tuning or reinforc-
ing association signals with nearby markers not
included in the “wet” genotyping experiment, are some
very interesting applications.4 However, one must bear
in mind that imputation depends on a reference panel
(HapMap CEU) that might not always accurately rep-
resent the particular population studied throughout
the genome, and certain regions might be more prone
to error than others. Indeed, even in our relatively
small study, PLINK imputation increased the number
of associated SNPs and expanded the association sig-
nal in 2 cases (YIPF5 and PPP6C) in accordance with
the strong LD surrounding the initially genotyped
variants (data not shown). The opposite occurs with
rs7040561 (PBX3), a strongly associated SNP located in
a region of very low LD that is untaggable by the
reference HapMap CEU SNP panel, thus obtaining a
low imputation quality value in the UK sample (INFO
value below the 0.8 threshold recommended in the
PLINK webpage). Even small fluctuations in allele fre-
quencies owing to imputation errors can have dra-
matic effects on the ability to detect a true association,
especially in the case of genes with a modest effect on
disease susceptibility, so it is advisable to be conserva-
tive with results obtained using imputed SNPs.
On the other hand, although Hunt et al underrate the
importance of genetic heterogeneity, this is a major issue
that cannot be overlooked. Population differences are at
least partly responsible for inconsistencies among studies
in CD, like the association of KIR genes (19q13 linkage
region) in Basque and Spanish CD patients,5 but not
detected in a UK study,6 or the numerous discordant
findings in CTLA4-ICOS (2q33) in different European
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